Talquetamab, the bispecific GPRC5D-directed CD3 T-cell engager, offered durable responses when used in different combinations, according to data from a pair of trials involving patients with multiple myeloma who had received 4 to 5 prior lines of therapy.
Updated phase 1b results were presented early Friday for the TRIMM-2 (NCT04108195) and RedirecTT (NCT04586426) trials at the International Myeloma Society 21st Annual Meeting & Exposition, taking place in Rio de Janiero, Brazil. Previous results for both studies were reported during the 2023 meeting of the American Society of Clinical Oncology (ASCO) and in the July 2023 issue of Evidence-Based Oncology™.1,2
Talquetamab (Talvey; Johnson & Johnson) was approved August 8, 2023, by FDA for the treatment of relapsed or refractory multiple myeloma in patients who have received at least 4 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.